Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, announced, on November 8, it has received a Peer-Reviewed Medical Research Program (PRMRP) Clinical Trial Award (CTA) grant for US $6.4 million from the U.S. Department of Defense (DOD).

In addition, the company is receiving advisory services and research and development funding of up to $2.8 Million from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

Financial support will enable Vasomune to accelerate clinical development of AV-001 for the Treatment of Patients with Severe COVID-19 Disease and COVID-associated ARDS.

Vasomune in an OBIO® member.